Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 971-977

  Galatin, Peter S ^a   Advani, Ranjana H ^a   Fisher, George A ^a   Francisco, Brian ^a   Julian, Thomas ^b   Losa, Raquel ^c   Sierra, Marta I ^c   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Genta Corporation   (United States)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Antisense oligonucleotide; Apoptosis; Bcl 2; Clinical trial; Gemcitabine; Oblimersen

Indexed keywords

GEMCITABINE; OBLIMERSEN; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DEOXYCYTIDINE; DRUG DERIVATIVE; NUCLEOTIDE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FEVER; FLATULENCE; HEADACHE; HEARTBURN; HEPATITIS; HUMAN; HYPERTENSION; HYPOTENSION; LIVER CIRRHOSIS; LYMPHADENITIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA; URINARY FREQUENCY; URINARY URGENCY; URTICARIA; VARICOSIS; VOMITING; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; GENETICS; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROTO ONCOGENE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BCL-2; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 84856069533     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9416-4     Document Type: Article

References (48)

1. Zimmerman KC, Green DR (2001) How cells die: apoptosis pathways. J Allergy Clin Immunol 108:S99-S103
2. Korsmeyer SJ et al (1993) Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4:327-332
3. Koty PP et al (2002) In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. Lung Cancer 35:155-163
4. Grizzle WE et al (2002) Molecular staging of colorectal cancer in African - American and Caucasian patients using phenotypic expression of p53, bcl-2, MUC-1 AND p27 (kip-1). Intl J Cancer 97:403-409
5. Scopa CD, Vagianos C, Kardamakis D et al (2001) Bcl-2/Bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 9(4):329-334
6. Ghanem MA, Kwast TH, Hollander JC et al (2001) The prognostic significance of apoptosis associated proteins bcl-2, bax and bcl-x in clinical nephroblastoma. Br J Cancer 85(10):1557-1563
7. Pich A, Chiusa L, Formiconi A et al (2001) Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low grade (grade1) papillary carcinomas of the bladder. Am J Surg path 25(12):1528-1533
8. Klasa RJ, List AF, Cheson BD (2001) Rational approaches to design of therapeutics targeting molecular markers. Hematology (Am Soc Hematol Educ Program): 443-462
9. Cotter FE et al (1996) Bcl-2 antisense therapy in lymphoma: in vitro and in vivo mechanisms, efficacy, pharmacokinetic and toxicity studies. Ann Oncol 7:A100
10. Rantenens MO, Joensuu H et al (2001) Causes and consequences of BCL2 overexpression in diffuse large B cell lymphoma. Leuk Lymphoma 42(5):1089-1098
11. Sartorius UA, Krammer PH (2002) Upregulaton of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer, 10, 97(5):584-592
12. Waters JS et al (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823
13. Gertz MA et al (2005) Early results of a Phase I trial of Oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma 5:282-284
14. Pro B et al (2008) Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lympho-ma. Br J Haematol 143:355-360
15. Marcucci G et al (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425-432
16. Marcucci G et al (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23:3404-3411
17. Moore J et al (2006) A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 30:777-783
18. O'Brien SM et al (2005) Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23:7697-7702
19. O'Brien S et al (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lympho-cytic leukemia. J Clin Oncol 25:1114-1120
20. O'Brien S et al (2009) 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 27:5208-5212
21. Van de Donk NW et al (2004) G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 18:1078-1084
22. Badros AZ et al (2005) Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalid-omide in relapsed multiple myeloma patients. J Clin Oncol 23:4089-4099
23. Chanan-Khan AA et al (2009) Phase III randomized study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 50:559-565
24. Rudin CM et al (2002) A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13:539-545
25. Rudin CM (2004) Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110-1117
26. Rudin CM et al (2008) Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26:870-876
27. Mita MM et al (2006) A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 17:313-321
28. Chi KN et al (2001) A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7:3920-3927
29. Tolcher AW (2004) A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10:5048-5057
30. Tolcher AW (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:3854-3861
31. Sternberg CN et al (2009) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20:1264-1269
32. Jansen B et al (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733
33. Bedikian AY et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745
34. Crino L et al (2001) Gemcitabine in advanced pancreatic cancer: a phase II trial. Am J Clin Oncol 24:296-298
35. Van Moorsel CJ et al (1997) Gemcitabine: future prospects of single-agent and combination studies. Oncologist 2:127-134
36. Santoro A et al (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 18:2615-2619
37. Fossa A et al (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 17:3786-3792
38. Zinzani PL et al (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603-2606
39. Grunewald R et al (1991) Saturation of 2', 2' difluorodeoxycitidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharm 27:258-262
40. Tempero M et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
41. Patel S et al (2001) Phase II clinical investigation of Gemcitabine in advanced soft tissue Sarcomas and window evaluation of dose rate on gemcitabine Triphosphate accumulation. J Clin Oncol 19:3483-3489
42. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
43. Losa R et al (2006) Simultaneous determination of gemcitabine di-and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 840:44-49
44. Scher HI et al (2000) A Phase I Trial of G3139 (Genta, Inc.), a BCL2 Antisense Drug, by Continuous Infusion (CI) as a Single Agent and with Weekly Taxol (T) (Meeting Abstract). Proc ASCO 19, A774
45. Marshall J et al (2004) A phase I study of Bcl-2 antisense G3139 and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 15(8):1274-1283
46. Morris MJ et al (2002) Phase I trial of BCL-2 antisense oligonucle-otide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8(3):678-683
47. Margolin K et al (2007) Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol 133(10):705-711
48. Raynaud FI et al (1997) Pharmacokinetics of G3139, a phosphor-othioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-427